Andrew J Pollard

List of Publications by Year
in descending order

354 papers	34,453 citations	7551 77 h-index	5227 165 g-index
387 all docs	387 docs citations	387 times ranked	38736 citing authors

#	Article	IF	Citations
1	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, The, 2021, 397, 99-111.	6.3	3,887
2	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
3	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196
4	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 2021, 384, 1885-1898.	13.9	1,077
5	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
6	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell, 2021, 184, 2348-2361.e6.	13.5	936
7	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nature Medicine, 2021, 27, 2032-2040.	15.2	900
8	Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet, The, 2021, 397, 1023-1034.	6.3	885
9	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell, 2022, 185, 467-484.e15.	13.5	788
10	A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology, 2021, 21, 83-100.	10.6	709
11	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. Cell, 2021, 184, 4220-4236.e13.	13.5	630
12	Effect of disorder on Raman scattering of single-layer<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mrow><mml:mi>Mo</mml:mi><mml:msub><mml:mi mathvariant="normal">S</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:math>. Physical Review B, 2015, 91, .	1.1	553
13	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
14	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. Cell, 2022, 185, 2422-2433.e13.	13.5	532
15	Antibody evasion by the P.1 strain of SARS-CoV-2. Cell, 2021, 184, 2939-2954.e9.	13.5	519
16	What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infectious Diseases, The, 2021, 21, e26-e35.	4.6	500
17	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Medicine, 2021, 27, 270-278.	15.2	473
18	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell, 2021, 184, 2201-2211.e7.	13.5	442

#	Article	IF	Citations
19	Maintaining protection against invasive bacteria with proteinâ€“polysaccharide conjugate vaccines. Nature Reviews Immunology, 2009, 9, 213-220.	10.6	389
20	Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison. Lancet Infectious Diseases, The, 2020, 20, 1390-1400.	4.6	336
21	The Influence of Maternally Derived Antibody and Infant Age at Vaccination on Infant Vaccine Responses. JAMA Pediatrics, 2017, 171, 637.	3.3	332
22	The antigenic anatomy of SARS-CoV-2 receptor binding domain. Cell, 2021, 184, 2183-2200.e22.	13.5	331
23	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Lancet, The, 2022, 399, 521-529.	6.3	314
24	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. New England Journal of Medicine, 2016, 374, 1635-1646.	13.9	295
25	Safety and Immunogenicity of Novel Adenovirus Type 26â€“ and Modified Vaccinia Ankaraâ€“Vectored Ebola Vaccines. JAMA - Journal of the American Medical Association, 2016, 315, 1610.	3.8	266
26	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. Nature Medicine, 2021, 27, 279-288.	15.2	265
27	Diagnostic Test Accuracy of a 2-Transcript Host RNA Signature for Discriminating Bacterial vs Viral Infection in Febrile Children. JAMA - Journal of the American Medical Association, 2016, 316, 835.	3.8	263
28	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	13.5	262
29	Multifunctional Nanoprobes for Nanoscale Chemical Imaging and Localized Chemical Delivery at Surfaces and Interfaces. Angewandte Chemie - International Edition, 2011, 50, 9638-9642.	7.2	256
30	Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet, The, 2017, 390, 2472-2480.	6.3	251
31	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. JAMA - Journal of the American Medical Association, 2012, 307, 573-82.	3.8	247
32	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet, The, 2014, 384, 2123-2131.	6.3	247
33	Multicenter, Openâ€Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy. Clinical Infectious Diseases, 2010, 51, 1127-1137.	2.9	235
34	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet, The, 2021, 398, 981-990.	6.3	214
35	Harnessing the beneficial heterologous effects of vaccination. Nature Reviews Immunology, 2016, 16, 392-400.	10.6	213
36	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. JAMA - Journal of the American Medical Association, 2008, 299, 173-84.	3.8	194

#	Article	IF	Citations
37	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
38	Antibody testing for COVID-19: A report from theÂNational COVID Scientific Advisory Panel. Wellcome Open Research, 2020, 5, 139.	0.9	179
39	Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1853-1858.	3.3	176
40	A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 2022, 185, 916-938.e58.	13.5	164
41	Meningococcal polysaccharideâ€“protein conjugate vaccines. Lancet Infectious Diseases, The, 2005, 5, 21-30.	4.6	163
42	Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Archives of Disease in Childhood, 2016, 101, 140-146.	1.0	157
43	Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life. Pediatric Infectious Disease Journal, 2010, 29, e71-e79.	1.1	151
44	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	5.8	150
45	Antiviral surfaces and coatings and their mechanisms of action. Communications Materials, 2021, 2, .	2.9	149
46	Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal. New England Journal of Medicine, 2019, 381, 2209-2218.	13.9	147
47	Global Epidemiology of Meningococcal Disease and Vaccine Efficacy. Pediatric Infectious Disease Journal, 2004, 23, S274-S279.	1.1	142
48	Nucleation Control for Large, Single Crystalline Domains of Monolayer Hexagonal Boron Nitride via Si-Doped Fe Catalysts. Nano Letters, 2015, 15, 1867-1875.	4.5	139
49	The Clinical Application of MicroRNAs in Infectious Disease. Frontiers in Immunology, 2017, 8, 1182.	2.2	134
50	Understanding and Controlling Cu-Catalyzed Graphene Nucleation: The Role of Impurities, Roughness, and Oxygen Scavenging. Chemistry of Materials, 2016, 28, 8905-8915.	3.2	128
51	An Outpatient, Ambulant-Design, Controlled Human Infection Model Using Escalating Doses of Salmonella Typhi Challenge Delivered in Sodium Bicarbonate Solution. Clinical Infectious Diseases, 2014, 58, 1230-1240.	2.9	126
52	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. Lancet HIV,the, 2021, 8, e568-e580.	2.1	124
53	The epidemiology of meningococcal disease and the impact of vaccines. Expert Review of Vaccines, 2010, 9, 285-298.	2.0	116
54	Identification of Antigen-Specific B Cell Receptor Sequences Using Public Repertoire Analysis. Journal of Immunology, 2015, 194, 252-261.	0.4	115

#	Article	IF	Citations
55	Studying the antibody repertoire after vaccination: practical applications. Trends in Immunology, 2014, 35, 319-331.	2.9	110
56	Chimpanzee adenovirusâ€“ and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science Translational Medicine, 2015, 7, 300ra126.	5.8	109
57	AS03- and MF59-Adjuvanted Influenza Vaccines in Children. Frontiers in Immunology, 2017, 8, 1760.	2.2	109
58	Supramolecular Assemblies Formed on an Epitaxial Graphene Superstructure. Angewandte Chemie - International Edition, 2010, 49, 1794-1799.	7.2	108
59	Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. Blood, 2009, 114, 4998-5002.	0.6	107
60	Serogroup B meningococcal vaccinesâ€”an unfinished story. Lancet Infectious Diseases, The, 2010, 10, 112-124.	4.6	107
61	Design, recruitment, and microbiological considerations in human challenge studies. Lancet Infectious Diseases, The, 2015, 15, 840-851.	4.6	107
62	MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella ParatyphiÂA. Nature Communications, 2018, 9, 253.	5.8	107
63	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. Cell, 2022, 185, 2116-2131.e18.	13.5	105
64	Vaccine prevention of meningococcal disease, coming soon?. Vaccine, 2001, 20, 666-687.	1.7	102
65	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
66	Consensus summary report for CEPI/BC March 12â€“13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines. Vaccine, 2020, 38, 4783-4791.	1.7	102
67	Global epidemiology of meningococcal disease and vaccine efficacy. Pediatric Infectious Disease Journal, 2004, 23, S274-9.	1.1	102
68	The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response. Journal of Immunology, 2008, 180, 2165-2173.	0.4	101
69	Non-specific effects of vaccines: plausible and potentially important, but implications uncertain. Archives of Disease in Childhood, 2017, 102, 1077-1081.	1.0	101
70	CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood, 2006, 108, 2642-2647.	0.6	99
71	Why the elderly appear to be more severely affected by <scp>COVID</scp>â€19: The potential role of immunosenescence and <scp>CMV</scp>. Reviews in Medical Virology, 2020, 30, e2144.	3.9	98
72	Immunological Memory. JAMA - Journal of the American Medical Association, 2005, 294, 3019.	3.8	96

#	Article	IF	Citations
73	Hospital admission rates for meningitis and septicaemia caused by Haemophilus influenzae, Neisseria meningitidis, and Streptococcus pneumoniae in children in England over five decades: a population-based observational study. Lancet Infectious Diseases, The, 2014, 14, 397-405.	4.6	96
74	Enter B and W: two new meningococcal vaccine programmes launched. Archives of Disease in Childhood, 2016, 101, 91-95.	1.0	94
75	In-Depth Assessment of Within-Individual and Inter-Individual Variation in the B Cell Receptor Repertoire. Frontiers in Immunology, 2015, 6, 531.	2.2	92
76	Analysis of B Cell Repertoire Dynamics Following Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences. EBioMedicine, 2015, 2, 2070-2079.	2.7	92
77	Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate Vaccine. Pediatric Infectious Disease Journal, 2005, 24, 128-131.	1.1	91
78	Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine. Vaccine, 2013, 31, 2852-2861.	1.7	90
79	Should children be vaccinated against COVID-19?. Archives of Disease in Childhood, 2022, 107, e1.4-e8.	1.0	89
80	MAIT cell activation augments adenovirus vector vaccine immunogenicity. Science, 2021, 371, 521-526.	6.0	88
81	Unlocking thermogravimetric analysis (TGA) in the fight against â€œFake grapheneâ€•materials. Carbon, 2021, 179, 505-513.	5.4	88
82	Nanoscale chemical imaging using tip-enhanced Raman spectroscopy. Nature Protocols, 2019, 14, 1169-1193.	5.5	86
83	Ethical Criteria for Human Challenge Studies in Infectious Diseases: Table 1.. Public Health Ethics, 2016, 9, 92-103.	0.4	84
84	BCR repertoire sequencing: different patterns of Bâ€¢cell activation after two Meningococcal vaccines. Immunology and Cell Biology, 2015, 93, 885-895.	1.0	83
85	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike proteinâ€“specific T _H 1 response with a diverse TCR repertoire. Science Translational Medicine, 2021, 13, eabj7211.	5.8	80
86	Reconsideration of the Use of Meningococcal Polysaccharide Vaccine. Pediatric Infectious Disease Journal, 2007, 26, 716-722.	1.1	79
87	Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after Immunization. Clinical Infectious Diseases, 2006, 43, 1387-1394.	2.9	77
88	Protection by vaccination of children against typhoid fever with a Vi-tetanus toxoid conjugate vaccine in urban Bangladesh: a cluster-randomised trial. Lancet, The, 2021, 398, 675-684.	6.3	77
89	Vaccines for prevention of meningococcal disease. Pediatric Infectious Disease Journal, 2000, 19, 333-344.	1.1	74
90	Global emergence and population dynamics of divergent serotype 3 CC180 pneumococci. PLoS Pathogens, 2018, 14, e1007438.	2.1	74

#	Article	IF	Citations
91	Haemophilus influenzae Type b Vaccine Failure in Children Is Associated with Inadequate Production of High-Quality Antibody. Clinical Infectious Diseases, 2008, 46, 186-192.	2.9	72
92	Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England. Lancet Public Health, The, 2017, 2, e367-e374.	4.7	72
93	Laboratory and molecular surveillance of paediatric typhoidal Salmonella in Nepal: Antimicrobial resistance and implications for vaccine policy. PLoS Neglected Tropical Diseases, 2018, 12, e0006408.	1.3	70
94	Non-specific immunological effects of selected routine childhood immunisations: systematic review. BMJ, The, 2016, 355, i5225.	3.0	69
95	Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. Cmaj, 2013, 185, E715-E724.	0.9	68
96	Nanoscale chemical imaging of solidâ€“liquid interfaces using tip-enhanced Raman spectroscopy. Nanoscale, 2018, 10, 1815-1824.	2.8	68
97	Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Tropical Diseases, 2016, 10, e0004926.	1.3	67
98	Salmonella Typhi-specific multifunctional CD8+ T cells play a dominant role in protection from typhoid fever in humans. Journal of Translational Medicine, 2016, 14, 62.	1.8	67
99	B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation. Genome Medicine, 2016, 8, 68.	3.6	64
100	Typhoid and paratyphoid fever: a call to action. Current Opinion in Infectious Diseases, 2018, 31, 440-448.	1.3	64
101	Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants. JAMA - Journal of the American Medical Association, 2005, 293, 1751.	3.8	63
102	Rapid and Fatal Meningococcal Disease Due to a Strain of Neisseria meningitidis Containing the Capsule Null Locus. Clinical Infectious Diseases, 2005, 40, e38-e42.	2.9	63
103	Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial. BMJ: British Medical Journal, 2006, 333, 571.	2.4	62
104	In Situ Graphene Growth Dynamics on Polycrystalline Catalyst Foils. Nano Letters, 2016, 16, 6196-6206.	4.5	62
105	Quantitative characterization of defect size in graphene using Raman spectroscopy. Applied Physics Letters, 2014, 105, .	1.5	61
106	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. Journal of Infection, 2015, 71, 43-52.	1.7	61
107	The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys. BMJ Open, 2017, 7, e016283.	0.8	61
108	Evaluation of the Clinical and Microbiological Response to Salmonella Paratyphi A Infection in the First Paratyphoid Human Challenge Model. Clinical Infectious Diseases, 2017, 64, 1066-1073.	2.9	60

#	Article	IF	Citations
109	Raman Fingerprints of Graphene Produced by Anodic Electrochemical Exfoliation. Nano Letters, 2020, 20, 3411-3419.	4.5	59
110	Serotype-Specific and Age-Dependent Generation of Pneumococcal Polysaccharide-Specific Memory B-Cell and Antibody Responses to Immunization with a Pneumococcal Conjugate Vaccine. Vaccine Journal, 2008, 15, 182-193.	3.2	57
111	Kinetics of the Natural, Humoral Immune Response toSalmonella entericaSerovar Typhi in Kathmandu, Nepal. Vaccine Journal, 2009, 16, 1413-1419.	3.2	57
112	Emergency management of meningococcal disease: eight years on. Archives of Disease in Childhood, 2007, 92, 283-286.	1.0	56
113	The kinetics and phenotype of the human B-cell response following immunization with a heptavalent pneumococcal-CRM197conjugate vaccine. Immunology, 2006, 119, 328-337.	2.0	52
114	A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infectious Diseases, The, 2014, 14, 426-434.	4.6	50
115	Activation of Salmonella Typhi-Specific Regulatory T Cells in Typhoid Disease in a Wild-Type S. Typhi Challenge Model. PLoS Pathogens, 2015, 11, e1004914.	2.1	50
116	Long-term protection after immunization with proteinâ€“polysaccharide conjugate vaccines in infancy. Expert Review of Vaccines, 2011, 10, 673-684.	2.0	49
117	The challenge of enteric fever. Journal of Infection, 2014, 68, S38-S50.	1.7	49
118	Covalent Carbene Functionalization of Graphene: Toward Chemical Band-Gap Manipulation. ACS Applied Materials & Interfaces, 2016, 8, 4870-4877.	4.0	49
119	Challenge of Humans with Wild-type Salmonella enterica Serovar Typhi Elicits Changes in the Activation and Homing Characteristics of Mucosal-Associated Invariant T Cells. Frontiers in Immunology, 2017, 8, 398.	2.2	47
120	Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination. Lancet, The, 2021, 398, 1683-1684.	6.3	47
121	Humoral Immune Responses toNeisseria meningitidisin Children. Infection and Immunity, 1999, 67, 2441-2451.	1.0	46
122	Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine, 2004, 22, 4262-4269.	1.7	45
123	Interferon-driven alterations of the hostâ€™s amino acid metabolism in the pathogenesis of typhoid fever. Journal of Experimental Medicine, 2016, 213, 1061-1077.	4.2	45
124	Vi-specific serological correlates of protection for typhoid fever. Journal of Experimental Medicine, 2021, 218, .	4.2	45
125	Immunogenicity and induction of immunological memory of the heptavalent pneumococcal conjugate vaccine in preterm UK infants. Vaccine, 2007, 25, 264-271.	1.7	44
126	Polysaccharide-specific B cell responses to vaccination in humans. Human Vaccines and Immunotherapeutics, 2014, 10, 1661-1668.	1.4	42

#	Article	IF	Citations
127	Burden of enteric fever at three urban sites in Africa and Asia: a multicentre population-based study. The Lancet Global Health, 2021, 9, e1688-e1696.	2.9	42
128	Production of few-layer graphene by microfluidization. Materials Research Express, 2017, 4, 025604.	0.8	41
129	Transcriptomics in Human Challenge Models. Frontiers in Immunology, 2017, 8, 1839.	2.2	41
130	Assessment of immune response to meningococcal disease: comparison of a whole-blood assay and the serum bactericidal assay. Microbial Pathogenesis, 1999, 27, 207-214.	1.3	40
131	How Does Graphene Grow? Easy Access to Wellâ€Ordered Graphene Films. Small, 2009, 5, 2291-2296.	5.2	40
132	Typhoid epidemiology, diagnostics and the human challenge model. Current Opinion in Gastroenterology, 2014, 30, 7-17.	1.0	40
133	Advancing the management and control of typhoid fever: A review of the historical role of human challenge studies. Journal of Infection, 2014, 68, 405-418.	1.7	40
134	A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. Journal of Infection, 2015, 71, 326-337.	1.7	40
135	IgA and IgG1 Specific to Vi Polysaccharide of Salmonella Typhi Correlate With Protection Status in a Typhoid Fever Controlled Human Infection Model. Frontiers in Immunology, 2019, 10, 2582.	2.2	40
136	High-Resolution Electrochemical and Topographical Imaging Using Batch-Fabricated Cantilever Probes. Analytical Chemistry, 2014, 86, 5143-5149.	3.2	39
137	Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses. Pediatric Infectious Disease Journal, 2013, 32, 1116-1121.	1.1	38
138	Searching for the human genetic factors standing in the way of universally effective vaccines. Philosophical Transactions of the Royal Society B: Biological Sciences, 2015, 370, 20140341.	1.8	38
139	Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans. PLoS Neglected Tropical Diseases, 2015, 9, e0004029.	1.3	38
140	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. Nature Communications, 2021, 12, 5861.	5.8	38
141	Plasma and memory Bâ€cell kinetics in infants following a primary schedule of CRM₁₉₇â€conjugated serogroup C meningococcal polysaccharide vaccine. Immunology, 2009, 127, 134-143.	2.0	37
142	Childhood meningitis in the conjugate vaccine era: a prospective cohort study. Archives of Disease in Childhood, 2015, 100, 292-294.	1.0	37
143	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). SSRN Electronic Journal, 0, , .	0.4	36
144	The Role Familiarity With Science and Medicine Plays in Parentsâ€™ Decision Making About Enrolling a Child in Vaccine Research. Qualitative Health Research, 2007, 17, 311-322.	1.0	35

#	Article	IF	Citations
145	Probing individual point defects in graphene via near-field Raman scattering. Nanoscale, 2015, 7, 19413-19418.	2.8	35
146	The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations. Vaccine, 2019, 37, 3190-3198.	1.7	35
147	Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age. Pediatric Infectious Disease Journal, 2014, 33, 760-766.	1.1	34
148	Blood culture-PCR to optimise typhoid fever diagnosis after controlled human infection identifies frequent asymptomatic cases and evidence of primary bacteraemia. Journal of Infection, 2017, 74, 358-366.	1.7	34
149	A New Combination Haemophilus influenzae Type B and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine for Primary Immunization of Infants. Pediatric Infectious Disease Journal, 2007, 26, 1057-1059.	1.1	33
150	Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model. Nature Medicine, 2019, 25, 1082-1088.	15.2	33
151	The serodominant secreted effector protein of Salmonella, SseB, is a strong CD4 antigen containing an immunodominant epitope presented by diverse <scp>HLA</scp> class <scp>II</scp> alleles. Immunology, 2014, 143, 438-446.	2.0	32
152	Identification of Novel Serodiagnostic Signatures of Typhoid Fever Using a Salmonella Proteome Array. Frontiers in Microbiology, 2017, 8, 1794.	1.5	32
153	Incomplete penetrance for isolated congenital asplenia in humans with mutations in translated and untranslated RPSA exons. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E8007-E8016.	3.3	31
154	Controlled human infection for vaccination against Streptococcus pyogenes (CHIVAS): Establishing a group A Streptococcus pharyngitis human infection study. Vaccine, 2019, 37, 3485-3494.	1.7	31
155	Disease Susceptibility to ST11 Complex Meningococci Bearing Serogroup C or W135 Polysaccharide Capsules, North America1. Emerging Infectious Diseases, 2004, 10, 1812-1815.	2.0	30
156	Developing a new justification for assent. BMC Medical Ethics, 2016, 17, 2.	1.0	30
157	Importance of Salmonella Typhi-Responsive CD8+ T Cell Immunity in a Human Typhoid Fever Challenge Model. Frontiers in Immunology, 2017, 8, 208.	2.2	30
158	Priorities for developing respiratory syncytial virus vaccines in different target populations. Science Translational Medicine, 2020, 12, .	5.8	30
159	Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. Cmaj, 2015, 187, E215-E223.	0.9	29
160	Human challenge trials in vaccine development, Rockville, MD, USA, September 28â€“30, 2017. Biologicals, 2019, 61, 85-94.	0.5	29
161	Persistence of Immunity Following a Booster Dose of Haemophilus Influenzae Type B-Meningococcal Serogroup C Glycoconjugate Vaccine. Pediatric Infectious Disease Journal, 2011, 30, 197-202.	1.1	28
162	Viral vector vaccines. Current Opinion in Immunology, 2022, 77, 102210.	2.4	28

#	Article	IF	Citations
163	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. BMJ, The, 2015, 350, h1554-h1554.	3.0	27
164	Clonal analysis of Salmonella-specific effector T cells reveals serovar-specific and cross-reactive T cell responses. Nature Immunology, 2018, 19, 742-754.	7.0	27
165	Determining the Level and Location of Functional Groups on Few-Layer Graphene and Their Effect on the Mechanical Properties of Nanocomposites. ACS Applied Materials & Interfaces, 2020, 12, 13481-13493.	4.0	27
166	Prospects for prevention of Salmonella infection in children through vaccination. Current Opinion in Infectious Diseases, 2013, 26, 254-262.	1.3	26
167	Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. Cell Reports, 2019, 27, 3241-3253.e4.	2.9	26
168	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. Clinical Infectious Diseases, 2019, 68, 1265-1273.	2.9	26
169	Payment in challenge studies: ethics, attitudes and a new payment for risk model. Journal of Medical Ethics, 2020, 46, 815-826.	1.0	26
170	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight, 2022, 7, .	2.3	26
171	Eligibility of overseas visitors and people of uncertain residential status for NHS treatment. BMJ: British Medical Journal, 2004, 329, 346-349.	2.4	25
172	Structural, chemical and electrical characterisation of conductive graphene-polymer composite films. Applied Surface Science, 2017, 403, 403-412.	3.1	25
173	Visualizing variation within Global Pneumococcal Sequence Clusters (GPSCs) and country population snapshots to contextualize pneumococcal isolates. Microbial Genomics, 2020, 6, .	1.0	25
174	Immunogenicity and Immunologic Memory of Meningococcal C Conjugate Vaccine in Premature Infants. Pediatric Infectious Disease Journal, 2005, 24, 966-968.	1.1	24
175	Longâ€Term Immunological Followâ€Up of Children withHaemophilus influenzaeSerotype b Vaccine Failure in the United Kingdom. Clinical Infectious Diseases, 2009, 49, 372-380.	2.9	24
176	B Cell Memory to a Serogroup C Meningococcal Conjugate Vaccine in Childhood and Response to Booster: Little Association with Serum IgG Antibody. Journal of Immunology, 2012, 189, 2673-2681.	0.4	24
177	Group B meningococcal vaccine: recommendations for UK use. Lancet, The, 2014, 383, 1103-1104.	6.3	24
178	Removal of Organic Contamination from Graphene with a Controllable Mass-Selected Argon Gas Cluster Ion Beam. Journal of Physical Chemistry C, 2015, 119, 17836-17841.	1.5	24
179	Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1â€“4 cross-sectional survey results. Lancet Infectious Diseases, The, 2021, 21, 677-687.	4.6	24
180	Evaluation of a Diagnostic Polymerase Chain Reaction Assay forNeisseria meningitidisin North America and Field Experience During an Outbreak. Archives of Pathology and Laboratory Medicine, 2002, 126, 1209-1215.	1.2	24

#	Article	IF	Citations
181	Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatric Infectious Disease Journal, 2003, 22, 659-660.	1.1	23
182	Social Mixing with Other Children during Infancy Enhances Antibody Response to a Pneumococcal Conjugate Vaccine in Early Childhood. Vaccine Journal, 2007, 14, 593-599.	3.2	23
183	Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Archives of Disease in Childhood, 2013, 98, 686-691.	1.0	23
184	An evaluation of purified Salmonella Typhi protein antigens for the serological diagnosis of acute typhoid fever. Journal of Infection, 2017, 75, 104-114.	1.7	23
185	Integrated Wafer Scale Growth of Single Crystal Metal Films and High Quality Graphene. ACS Nano, 2020, 14, 13593-13601.	7.3	23
186	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6â€“17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet, The, 2022, 399, 2212-2225.	6.3	23
187	Prevalence and decay of maternal pneumococcal and meningococcal antibodies: A meta-analysis of type-specific decay rates. Vaccine, 2017, 35, 5850-5857.	1.7	22
188	Decoupling of omicron variant infections and severe COVID-19. Lancet, The, 2022, 399, 1047-1048.	6.3	22
189	Childhood immunisation: what is the future?. Archives of Disease in Childhood, 2007, 92, 426-433.	1.0	21
190	Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Review of Vaccines, 2009, 8, 729-745.	2.0	21
191	The Role and Control of Residual Bulk Oxygen in the Catalytic Growth of 2D Materials. Journal of Physical Chemistry C, 2019, 123, 16257-16267.	1.5	21
192	Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). The Cochrane Library, 2019, 2019, CD008669.	1.5	21
193	Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model. PLoS Neglected Tropical Diseases, 2019, 13, e0007955.	1.3	21
194	The meningococcus tamed?. Archives of Disease in Childhood, 2002, 87, 13-17.	1.0	20
195	The capsular group B meningococcal vaccine, 4CMenB: clinical experience and potential efficacy. Expert Opinion on Biological Therapy, 2015, 15, 131-142.	1.4	20
196	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. Nature Communications, 2022, 13, 1251.	5.8	20
197	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. Clinical Microbiology and Infection, 2022, 28, 1649.e1-1649.e8.	2.8	20
198	The Effect of Chronic Cytomegalovirus Infection on Pneumococcal Vaccine Responses. Journal of Infectious Diseases, 2014, 209, 1635-1641.	1.9	19

#	Article	IF	Citations
199	The science of vaccine safety: Summary of meeting at Wellcome Trust. Vaccine, 2020, 38, 1869-1880.	1.7	19
200	The importance of international standards for the graphene community. Nature Reviews Physics, 2021, 3, 233-235.	11.9	19
201	Duration of intravenous antibiotic therapy for children with acute osteomyelitis or septic arthritis: a feasibility study. Health Technology Assessment, 2017, 21, 1-164.	1.3	19
202	Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. Archives of Disease in Childhood, 2013, 98, 248-251.	1.0	18
203	Oral Wild-Type Salmonella Typhi Challenge Induces Activation of Circulating Monocytes and Dendritic Cells in Individuals Who Develop Typhoid Disease. PLoS Neglected Tropical Diseases, 2015, 9, e0003837.	1.3	18
204	Effectiveness Analyses May Underestimate Protection of Infants after Group C Meningococcal Immunization. Journal of Infectious Diseases, 2006, 194, 231-237.	1.9	17
205	Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine. Vaccine Journal, 2012, 19, 295-303.	3.2	17
206	RSV vaccine use â€“ the missing data. Expert Review of Vaccines, 2016, 15, 149-152.	2.0	17
207	Salmonella Typhi Bactericidal Antibodies Reduce Disease Severity but Do Not Protect against Typhoid Fever in a Controlled Human Infection Model. Frontiers in Immunology, 2018, 8, 1916.	2.2	17
208	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. PLoS ONE, 2015, 10, e0129555.	1.1	17
209	Meningococcal Vaccines. Paediatric Drugs, 2004, 6, 251-266.	1.3	16
210	Assessment of T-dependent and T-independent immune responses in cattle using a B cell ELISPOT assay. Veterinary Research, 2012, 43, 68.	1.1	16
211	The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. Vaccine, 2013, 31, 2441-2448.	1.7	16
212	Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. BMJ Open, 2015, 5, e007481-e007481.	0.8	16
213	Reactive intercalation and oxidation at the buried graphene-germanium interface. APL Materials, 2019, 7, .	2.2	16
214	Gas physisorption measurements as a quality control tool for the properties of graphene/graphite powders. Carbon, 2020, 167, 585-595.	5.4	16
215	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. Nature Communications, 2021, 12, 5125.	5.8	16
216	W135 in Africa: origins, problems and perspectives. Travel Medicine and Infectious Disease, 2003, 1, 19-28.	1.5	15

#	Article	IF	Citations
217	Seroprevalence and Placental Transmission of Maternal Antibodies Specific for Neisseria meningitidis Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom. Pediatric Infectious Disease Journal, 2013, 32, 768-776.	1.1	15
218	Association between population prevalence of smoking and incidence of meningococcal disease in Norway, Sweden, Denmark and the Netherlands between 1975 and 2009: a population-based time series analysis. BMJ Open, 2014, 4, e003312.	0.8	15
219	High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. Genome Medicine, 2017, 9, 11.	3.6	15
220	Should we delay covid-19 vaccination in children?. BMJ, The, 2021, 374, n1687.	3.0	15
221	SIMON: Open-Source Knowledge Discovery Platform. Patterns, 2021, 2, 100178.	3.1	15
222	Homologous and heterologous re-challenge with Salmonella Typhi and Salmonella Paratyphi A in a randomised controlled human infection model. PLoS Neglected Tropical Diseases, 2020, 14, e0008783.	1.3	15
223	Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases. EMBO Molecular Medicine, 2019, 11, e10431.	3.3	15
224	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. Pediatric Infectious Disease Journal, 2016, 35, 787-793.	1.1	14
225	Terminology: the first step towards international standardisation of graphene and related 2D materials. Journal of Materials Science, 2017, 52, 13685-13688.	1.7	14
226	Physicochemical characterisation of reduced graphene oxide for conductive thin films. RSC Advances, 2018, 8, 37540-37549.	1.7	14
227	Nanoscale characterization of plasma functionalized graphitic flakes using tip-enhanced Raman spectroscopy. Journal of Chemical Physics, 2020, 153, 184708.	1.2	14
228	Recent advances in lipopolysaccharide-based glycoconjugate vaccines. Expert Review of Vaccines, 2021, 20, 1515-1538.	2.0	14
229	NONOPSONIC PHAGOCYTOSIS OF PSEUDOMONAS AERUGINOSA: INSIGHTS FROM AN INFANT WITH LEUKOCYTE ADHESION DEFICIENCY. Pediatric Infectious Disease Journal, 2001, 20, 452-454.	1.1	14
230	Vaccine nationalism and internationalism: perspectives of COVID-19 vaccine trial participants in the United Kingdom. BMJ Global Health, 2021, 6, e006305.	2.0	14
231	Meningococcal vaccines. Expert Review of Vaccines, 2002, 1, 75-84.	2.0	13
232	Epidemic meningococcal disease in sub-Saharan Africaâ€"towards a sustainable solution?. Lancet Infectious Diseases, The, 2003, 3, 68-70.	4.6	13
233	Differential post-transcriptional activation of human phagocytes by different Pseudomonas aeruginosa isolates. Cellular Microbiology, 2004, 6, 639-650.	1.1	13
234	Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C Neisseria meningitidis Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine. Pediatric Infectious Disease Journal, 2011, 30, e203-e208.	1.1	13

#	Article	IF	Citations
235	Metrology for graphene and 2D materials. Measurement Science and Technology, 2016, 27, 092001.	1.4	13
236	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. Cmaj, 2017, 189, E1276-E1285.	0.9	13
237	Assessment and Translation of the Antibody-in-Lymphocyte Supernatant (ALS) Assay to Improve the Diagnosis of Enteric Fever in Two Controlled Human Infection Models and an Endemic Area of Nepal. Frontiers in Microbiology, 2017, 8, 2031.	1.5	13
238	Emerging infectious diseases in the 21st century. Current Opinion in Infectious Diseases, 2000, 13, 265-275.	1.3	12
239	Vi polysaccharideâ€"protein conjugate vaccine for the prevention of typhoid fever in children: hope or hype?. Expert Review of Vaccines, 2007, 6, 293-295.	2.0	12
240	Sustaining immunity after immunization against encapsulated bacteria. Hum Vaccin, 2008, 4, 309-312.	2.4	12
241	Comparison of a limiting dilution assay and ELISpot for detection of memory B-cells before and after immunisation with a protein-polysaccharide conjugate vaccine in children. Journal of Immunological Methods, 2010, 358, 46-55.	0.6	12
242	Management of Respiratory Syncytial Virus Bronchiolitis: 2015 Survey of Members of the European Society for Paediatric Infectious Diseases. Canadian Journal of Infectious Diseases and Medical Microbiology, 2016, 2016, 1-5.	0.7	12
243	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. Vaccine, 2018, 36, 2300-2306.	1.7	12
244	Persistence of Antibody Response Following a Booster Dose of Hib-MenC-TT Glycoconjugate Vaccine to Five Years. Pediatric Infectious Disease Journal, 2012, 31, 1069-1073.	1.1	12
245	Ebola virus glycoprotein stimulates IL-18â€"dependent natural killer cell responses. Journal of Clinical Investigation, 2020, 130, 3936-3946.	3.9	12
246	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. PLoS ONE, 2014, 9, e91413.	1.1	12
247	National rates and disparities in childhood vaccination and vaccine-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database study. Archives of Disease in Childhood, 2022, 107, 733-739.	1.0	12
248	Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135. Expert Review of Vaccines, 2006, 5, 445-459.	2.0	11
249	Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study. Vaccine, 2015, 33, 4579-4585.	1.7	11
250	Viral bronchiolitis management in hospitals in the UK. Journal of Clinical Virology, 2018, 104, 29-33.	1.6	11
251	Vi-Vaccinations Induce Heterogeneous Plasma Cell Responses That Associate With Protection From Typhoid Fever. Frontiers in Immunology, 2020, 11, 574057.	2.2	11
252	RNA2HLA: HLA-based quality control of RNA-seq datasets. Briefings in Bioinformatics, 2021, 22, .	3.2	11

#	Article	IF	Citations
253	Evaluation of the Induction of Immune Memory following Infant Immunisation with Serogroup C Neisseria meningitidis Conjugate Vaccines â€“ Exploratory Analyses within a Randomised Controlled Trial. PLoS ONE, 2014, 9, e101672.	1.1	11
254	Immunologic memory with no detectable bactericidal antibody response to a first dose of meningococcal serogroup C conjugate vaccine at four years. Pediatric Infectious Disease Journal, 2003, 22, 659-61.	1.1	11
255	Challenges in immunisation against bacterial infection in children. Early Human Development, 2010, 86, 695-701.	0.8	10
256	Prevalence and Genetic Analysis of Phenotypically Vi- Negative Salmonella Typhi Isolates in Children from Kathmandu, Nepal. Journal of Tropical Pediatrics, 2013, 59, 317-320.	0.7	10
257	The use of systems biology and immunological big data to guide vaccine development. Genome Medicine, 2015, 7, 114.	3.6	10
258	Needle-Free Dermal Delivery of a Diphtheria Toxin CRM₁₉₇Mutant on Potassium-Doped Hydroxyapatite Microparticles. Vaccine Journal, 2015, 22, 586-592.	3.2	10
259	Control of invasive meningococcal disease. International Journal of Evidence-Based Healthcare, 2016, 14, 3-14.	0.1	10
260	The predicted persistence and kinetics of antibody decline 9 years after pre-school booster vaccination in UK children. Vaccine, 2016, 34, 4221-4228.	1.7	10
261	Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. Pediatric Infectious Disease Journal, 2017, 36, e130-e135.	1.1	10
262	Induction of Cell Cycle and NK Cell Responses by Live-Attenuated Oral Vaccines against Typhoid Fever. Frontiers in Immunology, 2017, 8, 1276.	2.2	10
263	Management of suspected paediatric meningitis: a multicentre prospective cohort study. Archives of Disease in Childhood, 2018, 103, 1114-1118.	1.0	10
264	Change in viral bronchiolitis management in primary care in the UK after the publication of NICE guideline. Thorax, 2018, 73, 674-676.	2.7	10
265	Comparative transcriptomics between species attributes reactogenicity pathways induced by the capsular group B meningococcal vaccine, 4CMenB, to the membrane-bound endotoxin of its outer membrane vesicle component. Scientific Reports, 2019, 9, 13797.	1.6	10
266	Mechanical properties of the hollow-wall graphene gyroid lattice. Acta Materialia, 2020, 201, 254-265.	3.8	10
267	Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. SSRN Electronic Journal, 0, . . .	0.4	10
268	An OMV Vaccine Derived from a Capsular Group B Meningococcus with Constitutive FetA Expression: Preclinical Evaluation of Immunogenicity and Toxicity. PLoS ONE, 2015, 10, e0134353.	1.1	9
269	Change in viral bronchiolitis management in hospitals in the UK after the publication of NICE guideline. Journal of Clinical Virology, 2018, 105, 84-87.	1.6	9
270	ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates â€“ Authors' reply. Lancet, The, 2021, 397, 2248.	6.3	9

#	Article	IF	Citations
271	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia. Wellcome Open Research, 2020, 5, 66.	0.9	9
272	Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh. Clinical Infectious Diseases, 2022, 75, 1681-1687.	2.9	9
273	Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. Vaccine, 2017, 35, 2701-2708.	1.7	8
274	Using nuclear magnetic resonance proton relaxation to probe the surface chemistry of carbon 2D materials. Nanoscale, 2021, 13, 6389-6393.	2.8	8
275	Should we be vaccinating children against COVID-19 in high-income countries?. Expert Review of Vaccines, 2021, 20, 1043-1046.	2.0	8
276	Electronic data capture for large scale typhoid surveillance, household contact tracing, and health utilisation survey: Strategic Typhoid Alliance across Africa and Asia. Wellcome Open Research, 2020, 5, 66.	0.9	8
277	New combination vaccines still need a boost. Archives of Disease in Childhood, 2007, 92, 1-2.	1.0	7
278	Alternative vaccine administration by powder injection: Needle-free dermal delivery of the glycoconjugate meningococcal group Y vaccine. PLoS ONE, 2017, 12, e0183427.	1.1	7
279	Meningococcal Capsular Group A, C, W, and Y Conjugate Vaccines. , 2018, , 619-643.e11.		7
280	Rapid monitoring of graphene exfoliation using NMR proton relaxation. Nanoscale, 2021, 13, 14518-14524.	2.8	7
281	Systems Immunology: Revealing Influenza Immunological Imprint. Viruses, 2021, 13, 948.	1.5	7
282	A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination. Microorganisms, 2021, 9, 1394.	1.6	7
283	Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. Molecular Systems Biology, 2020, 16, e9888.	3.2	7
284	Salmonella Typhi Vi capsule prime-boost vaccination induces convergent and functional antibody responses. Science Immunology, 2021, 6, eabj1181.	5.6	7
285	International interlaboratory comparison of Raman spectroscopic analysis of CVD-grown graphene. 2D Materials, 2022, 9, 035010.	2.0	7
286	Antibody Repertoire: Embracing Diversity. Science Translational Medicine, 2011, 3, 93ps32.	5.8	6
287	Group B meningococcal vaccine science and policy. Journal of Infection, 2015, 71, S15-S20.	1.7	6
288	Meningococcal Capsular Group B Vaccines. , 2018, , 644-662.e6.		6

#	Article	IF	Citations
289	Factors influencing participation in controlled human infection models: a pooled analysis from six enteric fever studies. Wellcome Open Research, 0, 4, 153.	0.9	6
290	Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles. PLoS ONE, 2016, 11, e0148840.	1.1	6
291	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. JCI Insight, 2022, 7, .	2.3	6
292	Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. Pediatric Infectious Disease Journal, 2013, 32, 675-681.	1.1	5
293	Investigations of the effect of SiC growth face on graphene thickness uniformity and electronic properties. Surface Topography: Metrology and Properties, 2015, 3, 015001.	0.9	5
294	Two centuries of immunisation in the UK (part II). Archives of Disease in Childhood, 2020, 105, 216-222.	1.0	5
295	Host restriction, pathogenesis and chronic carriage of typhoidalSalmonella. FEMS Microbiology Reviews, 2021, 45, .	3.9	5
296	Gas Cluster Ion Beam Cleaning of CVD-Grown Graphene for Use in Electronic Device Fabrication. ACS Applied Nano Materials, 2021, 4, 5187-5197.	2.4	5
297	Human B Cell Responses to Dominant and Subdominant Antigens Induced by a Meningococcal Outer Membrane Vesicle Vaccine in a Phase I Trial. MSphere, 2022, 7, e0067421.	1.3	5
298	Innovative vaccine approachesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1511, 59-86.	1.8	5
299	Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR. Journal of Clinical Microbiology, 2022, 60, e0228321.	1.8	5
300	Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers. Infection and Immunity, 2022, 90, e0038921.	1.0	5
301	Mucosal-Associated Invariant T cells exhibit distinct functional signatures associated with protection against typhoid fever. Cellular Immunology, 2022, 378, 104572.	1.4	5
302	Investigating Systemic Immunity to Typhoid and Paratyphoid Fever: Characterising the Response to Re-challenge in a Controlled Human Infection Model. Open Forum Infectious Diseases, 2017, 4, S227-S228.	0.4	4
303	ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 â€“ Authors' reply. Lancet, The, 2020, 396, 1486-1487.	6.3	4
304	Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants. Open Forum Infectious Diseases, 2020, 7, ofaa143.	0.4	4
305	Changes in epigenetic profiles throughout early childhood and their relationship to the response to pneumococcal vaccination. Clinical Epigenetics, 2021, 13, 29.	1.8	4
306	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. Wellcome Open Research, 2019, 4, 118.	0.9	4

#	Article	IF	Citations
307	International links between Streptococcus pneumoniae vaccine serotype 4 sequence type (ST) 801 in Northern European shipyard outbreaks of invasive pneumococcal disease. Vaccine, 2022, 40, 1054-1060.	1.7	4
308	Adjuvant Effects Elicited by Novel Oligosaccharide Variants of Detoxified Meningococcal Lipopolysaccharides on Neisseria meningitidis Recombinant PorA Protein: A Comparison in Mice. PLoS ONE, 2014, 9, e115713.	1.1	3
309	Investigation of CVD graphene topography and surface electrical properties. Surface Topography: Metrology and Properties, 2016, 4, 025001.	0.9	3
310	The effect of a single 4CMenB vaccine booster in young people more than ten years after infant immunisation: protocol of an exploratory immunogenicity study. Trials, 2019, 20, 455.	0.7	3
311	Identification of regulatory variants associated with genetic susceptibility to meningococcal disease. Scientific Reports, 2019, 9, 6966.	1.6	3
312	Human Salmonella Typhi exposure generates differential multifunctional crossâ€reactive Tâ€cell memory responses against Salmonella Paratyphi and invasive nontyphoidal Salmonella. Clinical and Translational Immunology, 2020, 9, e1178.	1.7	3
313	Depressive pseudodementia in a child with autism. Developmental Medicine and Child Neurology, 2004, 46, 485-9.	1.1	3
314	Distinct patterns of whole blood transcriptional responses are induced in mice following immunisation with adenoviral and poxviral vector vaccines encoding the same antigen. BMC Genomics, 2021, 22, 777.	1.2	3
315	Potential global impacts of alternative dosing regimen and rollout options for the ChAdOx1 nCoV-19 vaccine. Nature Communications, 2021, 12, 6370.	5.8	3
316	Understanding the bonding mechanisms of organic molecules deposited on graphene for biosensing applications. Journal of Chemical Physics, 2021, 155, 174703.	1.2	3
317	Adenovirus vectors activate VÎ2⁺ Î³Î´T cells in a type I interferonâ€, TNFâ€, and ILâ€18â€dependent manner. European Journal of Immunology, 2022, 52, 835-837.	1.6	3
318	Viral vectors expressing group B meningococcal outer membrane proteins induce strong antibody responses but fail to induce functional bactericidal activity. Journal of Infection, 2022, 84, 658-667.	1.7	3
319	Clinical trials: consent in children. Expert Review of Vaccines, 2005, 4, 1-3.	2.0	2
320	Benchmarking of Viral Bronchiolitis Management by General Practitioners in the United Kingdom. Pediatric, Allergy, Immunology, and Pulmonology, 2017, 30, 69-73.	0.3	2
321	Neisseria meningitidis. , 2018, , 747-759.e5.		2
322	Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. Pediatric Infectious Disease Journal, 2018, 37, e103-e106.	1.1	2
323	Two centuries of immunisation in the UK (part 1). Archives of Disease in Childhood, 2019, 105, archdischild-2019-317314.	1.0	2
324	Notice of addendum to Article reporting Oxford trial of ChAdOx1 nCoV-19 vaccine. Lancet, The, 2020, 396, e89.	6.3	2

#	Article	IF	Citations
325	Progress in the overall understanding of typhoid fever: implications for vaccine development. Expert Review of Vaccines, 2020, 19, 367-382.	2.0	2
326	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. SSRN Electronic Journal, 0, , .	0.4	2
327	Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination. Frontiers in Tropical Diseases, 2021, 2, .	0.5	2
328	Neisseria meningitidis. , 2008, , 734-743.		2
329	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. PLoS ONE, 2016, 11, e0165384.	1.1	2
330	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. Wellcome Open Research, 2019, 4, 118.	0.9	2
331	Inclusion of a dual signal sequence enhances the immunogenicity of a novel viral vectored vaccine against the capsular group B meningococcus. Cell and Bioscience, 2022, 12, .	2.1	2
332	Course of Disease and Clinical Management. , 2006, , 481-517.		1
333	Intussusception risk after rotavirus vaccination in England. Vaccine, 2016, 34, 6114.	1.7	1
334	A quantitative review of healthcare professionals' questions to a local immunization advice service: 4299 enquiries from 3 years. Journal of Public Health, 2016, 38, 578-584.	1.0	1
335	Bone and joint infections in Oxford: a 10-year retrospective review. Archives of Disease in Childhood, 2020, 105, 515-516.	1.0	1
336	Persistence of Antibody After a Vi-Tetanus Toxoid Conjugate Vaccine and Effect of Boosting With a Plain Polysaccharide Vaccine on Vi Antibody and Antigen-Specific B Cells. Frontiers in Tropical Diseases, 2021, 2, .	0.5	1
337	Incidental findings in UK healthy volunteers screened for a COVIDâ€19 vaccine trial. Clinical and Translational Science, 2021, , .	1.5	1
338	Neisseria meningitidis. , 2012, , 730-741.e7.		1
339	Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation. Vaccine, 2022, 40, 4453-4463.	1.7	1
340	Expert Review of Vaccines10-year anniversary issue. Expert Review of Vaccines, 2011, 10, 1489-1491.	2.0	0
341	Editorials. Indian Pediatrics, 2014, 51, 445-450.	0.2	0
342	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. Vaccine, 2016, 34, 6350-6357.	1.7	0

#	Article	IF	Citations
343	Preface. Journal of Infection, 2016, 72, 1.	1.7	0
344	Prevention of meningococcal disease through vaccination. , 2016, , 91-103.		0
345	Preface. Journal of Infection, 2017, 74, S1.	1.7	0
346	Trends in meningococcal disease: challenges for vaccine control when disease is rare. Medical Journal of Australia, 2017, 207, 380-381.	0.8	0
347	Graphene: civil engineering applications start to come to fruition. Proceedings of the Institution of Civil Engineers: Civil Engineering, 2018, 171, 15-15.	0.3	0
348	The Family Context of Assent: Comparison of Child and Parent Perspectives on Familial Decisionâ€Making. Children and Society, 2018, 32, 266-278.	1.0	0
349	Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies induced by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine, 2018, 36, 6988-6994.	1.7	0
350	What time interval is needed between the administration of live attenuated vaccines?. Archives of Disease in Childhood, 2020, 105, 1232-1235.	1.0	0
351	Vaccines for the Prevention of Admission to the Pediatric Intensive Care Unit. , 2008, , 143-175.		0
352	Meningococcal Disease. Ulster Medical Journal, 2018, 87, 81-82.	0.2	0
353	TIPICO XI: report of the first series and podcast on infectious diseases and vaccines (aTIPICO). Human Vaccines and Immunotherapeutics, 2021, 17, 4299-4327.	1.4	0
354	Future reporting of vaccine uptake needs to include any change in ethnic or socioeconomic disparities. BMJ, The, 2022, 377, o1233.	3.0	0